AU2022374097A1 - 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression - Google Patents

2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression Download PDF

Info

Publication number
AU2022374097A1
AU2022374097A1 AU2022374097A AU2022374097A AU2022374097A1 AU 2022374097 A1 AU2022374097 A1 AU 2022374097A1 AU 2022374097 A AU2022374097 A AU 2022374097A AU 2022374097 A AU2022374097 A AU 2022374097A AU 2022374097 A1 AU2022374097 A1 AU 2022374097A1
Authority
AU
Australia
Prior art keywords
fdck
administered
treatment
amount
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022374097A
Other languages
English (en)
Inventor
Ezekiel Golan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clearmind Labs Corp
Original Assignee
Clearmind Labs Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearmind Labs Corp filed Critical Clearmind Labs Corp
Publication of AU2022374097A1 publication Critical patent/AU2022374097A1/en
Assigned to CLEARMIND LABS CORP. reassignment CLEARMIND LABS CORP. Request for Assignment Assignors: Clearmind Medicine Inc.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022374097A 2021-10-18 2022-10-18 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression Pending AU2022374097A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256728P 2021-10-18 2021-10-18
US63/256,728 2021-10-18
PCT/IB2022/060011 WO2023067505A1 (en) 2021-10-18 2022-10-18 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression

Publications (1)

Publication Number Publication Date
AU2022374097A1 true AU2022374097A1 (en) 2024-03-14

Family

ID=84178934

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022374097A Pending AU2022374097A1 (en) 2021-10-18 2022-10-18 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression

Country Status (8)

Country Link
US (1) US20250032429A1 (https=)
EP (1) EP4419092A1 (https=)
JP (1) JP2024538015A (https=)
KR (1) KR20240093579A (https=)
CN (1) CN118401239A (https=)
AU (1) AU2022374097A1 (https=)
CA (1) CA3233107A1 (https=)
WO (1) WO2023067505A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094757A1 (en) * 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
CN119241381A (zh) * 2019-12-26 2025-01-03 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途

Also Published As

Publication number Publication date
US20250032429A1 (en) 2025-01-30
EP4419092A1 (en) 2024-08-28
CA3233107A1 (en) 2023-04-27
CN118401239A (zh) 2024-07-26
WO2023067505A1 (en) 2023-04-27
JP2024538015A (ja) 2024-10-18
KR20240093579A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
US20250032432A1 (en) Bupropion as a modulator of drug activity
US11273134B2 (en) Bupropion as a modulator of drug activity
US10945973B2 (en) Bupropion as a modulator of drug activity
US10772850B2 (en) Bupropion as a modulator of drug activity
US10898453B2 (en) Bupropion as a modulator of drug activity
US10966974B2 (en) Bupropion as a modulator of drug activity
US10874664B2 (en) Bupropion as a modulator of drug activity
US20210205297A1 (en) Bupropion as a modulator of drug activity
US20210069125A1 (en) Bupropion as a modulator of drug activity
KR20210110654A (ko) 우울증 치료를 위한 덱스트로메토르판과 부프로피온의 조합
KR20140136982A (ko) 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
EA010430B1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
Pabis et al. Pharmacotherapy of aggressive behavior
AU2016203771A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
US10576045B2 (en) Low dosage combinations of fluoxetine and reboxetine for treating obesity
Uddin et al. Amphetamines: Potent recreational drug of abuse
US20250032429A1 (en) 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression
CA3186900A1 (en) Compositions and methods for treating psychiatric disorders or symptoms thereof
Stock et al. Pharmacological treatment of paediatric
JP2025504069A (ja) オキシトシンを使用した治療方法
RU2477634C2 (ru) Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
Vyas 28 Pharmacology of Behavioral Disorders
Owens et al. Clinical psychopharmacology
AU2013201492A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AU2013203567A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CLEARMIND LABS CORP.

Free format text: FORMER APPLICANT(S): CLEARMIND MEDICINE INC.